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Introduction
Over the last decades the involvement of reactive oxygen 
species (ROS) in the molecular mechanisms related to 
psychiatric disorders such as depression or schizophrenia 
became evident.
1-3
 In rat models of depression a 
decreased activity of antioxidant enzymes such as 
glutathione peroxidase (GSH-Px) followed by increased 
lipid peroxidation were observed.
4-6
 Furthermore, in 
patients with depression the elevated plasma ROS levels 
were observed to effectively amplify oxidative stress.
7,8
 
All of these observations solidified the oxidative stress 
hypothesis of depression. 
As the removal of ROS is a vital element of 
antimutagenesis strategy, it was further suggested that 
the improvement in antimutagenic defense system may 
be one of the mechanisms underlying the neuroprotective 
effects of antidepressant drugs during depressive 
disorder therapies. Therefore, the development of new 
compounds with antidepressant properties which 
additionally display antimutagenic and possibly 
chemopreventive properties is of great practical and 
therapeutic significance.
9
  
To evaluate mutagenic activity of new compounds many 
short-term and highly sensitive tests were introduced.
10,11
 
A general strategy behind mutagenicity testing is to 
apply a diversified set of tests to cover all of the main 
mutagenicity endpoints. Another big challenge for 
mutagenicity assessment is the prospect for using 
alternative assays to animal testing i.e. in vitro and in 
silico test methods.  
The in vitro Ames/Salmonella test is a key tool for 
mutagenicity assessment and a substantial element of the 
official genotoxicity testing package
12
 required for 
accomplishing the preclinical evaluation. The test is 
suitable for the detection of molecules that cause 
mutations such as frame-shifts or base-pair 
substitutions.
13
 In the last several decades, several rapid 
bacterial mutagenicity tests have been developed and 
optimized, such as the Vibrio harveyi assay.
14,15
 The test 
involves a series of genetically modified strains of a 
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Abstract 
Purpose: Determination of the mutagenic potential of new biologically active compounds 
is of great concern for preliminary toxicity testing and drug development. 
Methods: The mutagenic and antimutagenic effects of some quinoline- and isoquinoline-
sulfonamide analogs of aripiprazole (1-8), which display potent antidepressant, anxiolytic, 
and antipsychotic properties, were evaluated using the Vibrio harveyi assay and OSIRIS 
Property Explorer software. Additionally, the Ames test was used as the reference.  
Results: In silico prediction showed that compounds 5 (N-(3-(4-(2,3-
dichlorophenyl)piperazin-1-yl)propyl)quinoline-7-sulfonamide) and 6 (N-(4-(4-(2,3-
Dichlorophenyl)piperazin-1-yl)butyl)quinoline-7-sulfonamide) trigger a mutagenic 
structural alert. However, this was not confirmed by in vitro assays, as none of the tested 
compounds displayed mutagenic activity against all tested strains of bacteria. Moreover, 
compounds 1-8 displayed a protective effect against the mutagenicity induced by a direct 
acting mutagen NQNO. The most beneficial antimutagenic properties showed compound 5 
which exhibited strong antimutagenic properties in all tested V. harveyi strains. High 
antimutagenic potency of this compound was confirmed in the Ames TA100 assay system. 
Conclusion: Newly synthesized azinesulfonamide analogs of aripiprazole may be 
considered as genotoxically safe as they do not display mutagenic activity on the tester 
strains. Moreover, the tested compounds demonstrated significant antimutagenic 
properties that can be valuable for prevention of the NQNO genotoxicity. Additionally, it 
appears that the Vibrio harveyi assay can be applied for primary mutagenicity and 
antimutagenicity assessment of chemical substances, thus, representing a useful 
alternative tool for compounds safety evaluation.  
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marine bacterium Vibrio harveyi. The sensitivity of this 
assay was found to be similar to, or even somewhat 
higher than, that of the commonly used the Ames test.
16
 
To prevent genotoxic risk it is pertinent to identify 
potential mutagens in order to minimize human exposure 
to them, as well as to enhance the exposure to 
antimutagenic agents. Thus, the present study was 
designed to evaluate the mutagenic and antimutagenic 
properties of the newly synthesized quinoline- and 
isoquinoline-sulfonamide analogs of aripiprazole (1–8) 
(Table 1) which behave as multimodal 
dopamine/serotonin agents and display antidepressant, 
anxiolytic, and/or antipsychotic properties.
17-19
 Focusing 
on the application of alternative in vitro and in silico test 
methods to predict compounds mutagenicity in the 
present study the Vibrio harveyi assay and OSIRIS 
Property Explorer software were employed. 
Additionally, the Ames test was used as the reference.  
 
Table 1. Binding of the quinoline- and isoquinoline-sulfonamides (1–xx) for the 5-HT and D receptors, and their pharmacological 
behavior.
17,18
 
 
Compd Azinyl Spacer n R 
Ki [nM] 
Forced swim test 
Potential antidepressant 
activity 
5-HT1A 5-HT2A 5-HT6 5-HT7 D2 D3
b
 MED [mg/kg]
c
 
1 
 
Flexible 1 3-Cl 52 22 139 56 40 70/94 10 
2 
 
Flexible 1 3-Cl 208 56 155 88 NT
d
 NT NT 
3 
 
Rigidified 2 4-Cl 3210 59 16650 47 60 67/93 30 
4 
 
Flexible 1 2,3-diCl 23 34 1331 30 9 94/99 10 
5 
PZ-549 
 
Flexible 0 2,3-diCl 14 47 257 12 16 90/99 5 
6 
 
Flexible 1 2,3-diCl 17 22 301 31 11 99/101 10 
7 
 
Flexible 1 2,3-diCl 34 35 454 56 17 95/98 5 
8 
 
Flexible 1 2,3-diCl 59 90 220 21 8 93/95 20 
Aripiprazole – – 2,3-diCl 5.6 21 90 26 0.8 9.7 NA
e
 
a
 Ki values (SEM ± 22) based on three independent binding experiments; 
b
 Screening procedure – displacement % at 10
–7
/10
–6
; 
c
 MED –
 minimal effective dose; 
d
 NT – not tested; 
e
 NA – not active. 
 
Materials and Methods 
Tested compounds and chemicals 
The tested compounds were synthesized in the 
Department of Medicinal Chemistry, Jagiellonian 
University Medical College by Zajdel et al.
17,18
 The 
compounds structures were established previously on the 
basis of CHN elemental analysis and spectral data 
(
1
HNMR and mass spectra).  
Dimethylsulfoxide (DMSO) of high grade purity (99,9%) 
was obtained from Merck, (Darmstadt, Germany). 4-
nitroquinoline-N-oxide (NQNO) chosen as positive 
control, was purchased from Sigma (Seelze, Germany). 
1 - 8
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The examined compounds were dissolved in DMSO to 
obtain the desired final test concentrations (i.e. 40 ng/ml 
for the Vibrio harveyi assay; 40 and 500 ng/ml for the 
Ames test) which were established in pilot experiments. 
It was demonstrated previously that in the Vibrio harveyi 
assay very low concentrations of mutagens could be 
detected.
20
 As regards the Ames test, two compounds 
concentrations were employed, namely the one used in 
the Vibrio harveyi assay and the higher one commonly 
used in the assay.
10,21,22
  
 
Bacterial strains 
Four Vibrio harveyi strains were used in the experiments: 
wild-type BB7 and genetically modified strains: BB7M, 
BB7X and BB7XM.
14-16
 These strains were kindly 
provided by Prof. G. Węgrzyn (University of Gdańsk, 
Poland). Salmonella typhimurium tester strain TA100, as 
described by Maron and Ames
13
 and Mortelmans and 
Zeiger,
10
 was kindly provided by Dr. T. Nohmi (National 
Institute of Hygienic Sciences, Tokyo, Japan).  
 
Culture media and growth conditions 
In the Ames test the minimal medium described 
previously by Maron and Ames
13
 was used. In case of 
the Vibrio harveyi assay BOSS medium was employed.
23
 
All strains were stored at 
_
80°C in 10% glycerol (final 
concentration).  
 
Mutagenicity assays  
Mutagenicity assays were performed as described 
previously by Maron and Ames
13
 and Czyż et al.
16
 All 
experiments were carried out in triplicate and the results 
were expressed as mutagenic index (M.I. = the number 
of revertant colonies induced in the tested sample/ the 
number of spontaneous revertants in the negative 
control).
14,15,24
 A compound was considered mutagenic 
when the M.I. was equal or greater than 2. 
 
Antimutagenicity assays  
Antymutagenicity assays were performed according to 
previously described procedures.
10,13-15,25 
Triplicate plates 
were set up with each test compound concentration and 
the entire experiment was repeated twice. The inhibition 
of mutagenicity was expressed as percentage decrease of 
mutant colonies and calculated using the following 
equation: Percent Inhibition = 100 – [(R1/R2) × 100], 
where R1 is the number of mutants per plate induced by 
test compound plus mutagen and R2 is the number of 
mutants per plate induced by mutagen alone.
26,27
 A 25–
40% inhibition was defined as moderate antigenotoxicity, 
40% or higher inhibition as strong antigenotoxicity, and 
25% or less inhibition as no antigenotoxicity.
24
  
 
In silico toxicity prediction 
The OSIRIS Property Explorer was used to predict 
mutagenicity of the compounds in the present study.
28-30
 
 
Results 
Mutagenic activity 
Table 2 presents a number of mutants per plate and 
mutagenic index (M.I.) for selected quinoline- and 
isoquinoline-sulfonamide analogs of aripiprazole (1–8) 
evaluated in V. harveyi strains. Additionally, Table 2 was 
supplemented with the results of in silico mutagenicity 
prediction of the tested compounds. On the basis of the 
OSIRIS prediction results it was noted that two of the 
tested compounds, namely 5 and 6 trigger a mutagenic 
structural alert.  
 
Table 2. Mutagenic activity of azinesulfonamides in the Vibrio harveyi test and by using OSIRIS Property Explorer. 
Compd 
Vibrio harveyi test  In silico 
BB7
a 
BB7X
a
 BB7M
a
 BB7XM
a
  OSIRIS 
 Mean ± S.D. M.I.
 c
 Mean ± S.D. M.I.
 c
 Mean ± S.D. M.I.
 c
 Mean ± S.D. M.I.
 c
 M
d
 
DMSO
b
 21 ± 4  17 ± 3  28 ± 2  16 ± 4   
NQNO
b
 42 ± 9 2 34 ± 8 2 58 ± 4 2.1 36 ± 7 2.3  
1 31 ± 6 1.5 27 ± 5 1.6 43 ± 5 1.5 27 ± 6 1.7 - 
2 22 ± 8 1.0 17 ± 5 1.0 46 ± 8 1.6 16 ± 3 1.0 - 
3 25 ± 7 1.2 15 ± 4 0.9 37 ± 9 1.3 23 ± 6 1.4 - 
4 27 ± 5 1.3 19 ± 5 1.1 33 ± 6 1.2 22 ± 7 1.4 - 
5 17 ± 3 0.8 6 ± 3 0.4 24 ± 2 0.9 15 ± 5 0.9 +/- 
6 15 ± 6 0.7 18 ± 6 1.1 32 ± 6 1.1 24 ± 7 1.5 +/- 
7 31 ± 5 1.5 14 ± 6 0.8 29 ± 1 1.0 17 ± 6 1.1 - 
8 25 ± 6 1.2 22 ± 4 1.3 34 ± 5 1.2 27 ± 4 1.7 - 
Aripiprazole 12 ± 3 0.6 3 ± 2 0.2 10 ± 3 0.4 5 ± 2 0.3 - 
a
Number of revertants; 
b
NQNO (nitroquinoline-N-oxide, 40 ng/ml) - positive control; DMSO - negative control;
c
M.I. (mutagenic 
index): number of induced revertants / number of spontaneous revertants; M
d
: mutagenicity.
 
 
 
The current in vitro study demonstrated that in a 
concentration of 40 ng/ml all of the tested compounds 
exhibited no mutagenic activity in V. harveyi BB7, 
BB7M, BB7X and BB7XM strains. Similarly, as shown 
 
 380  | Advanced Pharmaceutical Bulletin, 2016, 6(3), 377-384 
Powroźnik et al. 
in Table 3 the tested compounds were non mutagenic in 
the Ames TA100 mutagenicity assay when tested in two 
concentrations i.e. 40 and 500 ng/ml.  
 
Table 3. Mutagenic activity of azinesulfonamides in the Ames test. 
Compd 
Concentration 
(ng/ml) 
Ames test 
TA100
a
 
  Mean ± S.D. M.I.
c
 
DMSO
b
  10 ± 5  
NQNO
b
 40 31 ± 4 3.1 
 500 72 ± 10 7.2 
1 40 5 ± 2 0.5 
 500 8 ± 3 0.8 
2 40 3 ± 1 0.3 
 500 12 ± 4 1.2 
3 40 4 ± 2 0.4 
 500 6 ± 2 0.6 
4 40 8 ± 2 0.8 
 500 18 ± 4 1.8 
5 40 5 ± 2 0.5 
 500 9 ± 3 0.9 
6 40 7 ± 2 0.7 
 500 9 ± 3 0.9 
7 40 5 ± 2 0.5 
 500 8 ± 2 0.8 
8 40 4 ± 2 0.4 
 500 6 ± 3 0.6 
Aripiprazole 40 14 ± 4 1.4 
 500 19 ± 4 1.9 
 a
Number of revertants; 
b
NQNO (nitroquinoline-N-oxide, 40 
ng/ml, 500ng/ml) - positive control; DMSO - negative control; 
c
M.I. (mutagenic index): number of induced revertants / number 
of spontaneous revertants (positive assay when M.I.≥2); 
d
M: 
mutagenicity 
Antimutagenic activity 
The antimutagenic effects of the selected quinoline- and 
isoquinoline-sulfonamide derivatives (1–8) were 
examined against NQNO in V. harveyi BB7, BB7M, 
BB7X, BB7XM and in S. typhimurium TA100 strains. 
All of the tested compounds effectively reduced a 
number of mutations induced by a direct acting agent 
NQNO in all bacterial strains used in the experiment 
(Tables 4 and 5). 
In the Vibrio harveyi antimutagenicity assay 
compounds 4 and 5 demonstrated the highest 
antimutagenic activity against NQNO induced 
mutagenicity. The inhibition rates for these compounds 
were between 40% and 84%. It is worth noting, that 
only compound 5 exhibited strong antimutagenic 
properties in all tested V. harveyi strains. Aripiprazole 
also strongly inhibited the mutagenicity induced by 
NQNO in V. harveyi BB7XM assay system. In the 
remaining three strains the compound demonstrated 
moderate antimutagenic potential. Three of the tested 
compounds i.e. 2, 3 and 8 strongly reduced NQNO 
mutagenicity in V. harveyi strains BB7 and BB7XM. 
The inhibition percentages of these substances ranged 
from 41 to 65. For the remaining two strains these 
compounds demonstrated moderate antimutagenic 
activity (inhibition percentages between 28 and 38), 
except for compound 3 which showed weak 
antimutagenic potency in BB7M strain. Finally, 
compounds 6 and 7 strongly suppressed mutagen 
activity in one tested strain and moderately inhibited 
mutagenicity in the other three V. harveyi strains (Table 
4). 
 
Table 4. Antimutagenic activity of azinesulfonamides in the Vibrio harveyi test. 
Compd 
Vibrio harveyi test 
BB7
a
 BB7X
a
 BB7M
a
 BB7XM
a
 
Mean ± S.D. Inhib. (%)
c
 Mean ± S.D. 
Inhib. 
(%)
c
 
Mean ± S.D. 
Inhib. 
(%)
c
 
Mean ± S.D. 
Inhib. 
 (%)
c
 
DMSO 16 ± 4  13 ± 5  18 ± 4  11 ± 2  
NQNO 38 ± 6  32 ± 3  47 ± 5  34 ± 5  
1 17 ± 7 (55) 19 ± 5 (41) 34 ± 4 (28) 18 ± 4 (47) 
2 15 ± 5 (61) 20 ± 6 (38) 31 ± 3 (34) 20 ± 3 (41) 
3 17 ± 7 (55) 23 ± 3 (28) 36 ± 2 (23) 12 ± 3 (65) 
4 19 ± 6 (50) 17 ± 7 (47) 28 ± 5 (40) 16 ± 5 (53) 
5 6 ± 5 (84) 8 ± 2 (75) 9 ± 4 (81) 14 ± 5 (59) 
6 18 ± 2 (53) 25 ± 3 (22) 31 ± 7 (34) 23 ± 3 (32) 
7 24 ± 4 (37) 23 ± 5 (28) 29 ± 5 (38) 18 ± 2 (47) 
8 14 ± 6 (63) 20 ± 6 (38) 34 ± 4 (28) 12 ± 2 (65) 
Aripiprazole 21 ± 2 (45) 17 ± 5 (47) 22 ± 4 (53) 13 ± 2 (62) 
a
Number of revertants; 
b
NQNO (nitroquinoline-N-oxide, 40 ng/ml) - positive control; DMSO - negative control; 
c
The values in parenthesis 
are the inhibition rates (%) of mutagenicity. 
 
The results presented in Table 5 show that in S. 
typhimurium TA100 strain the strongest antimutagenic 
effect was observed for compound 5 with inhibition 
percentages of 48% (40 ng/ml) and 43% (500 ng/ml). 
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Three other compounds 1, 4 and 8 were strong inhibitors 
of the mutagenicity induced by a direct-acting mutagen 
NQNO only in one tested concentration. Compound 1 in 
a lower concentration inhibited NQNO mutagenicity by 
48%, whereas compound 4 when tested in higher 
concentration reduced NQNO - induced mutagenic effect 
by 51%. Aripiprazole used as a reference psychotropic 
drug inhibited the mutations induced by NQNO ranging 
from 27% to 30%, which indicates a moderate 
antimutagenic effect. Additionally, compounds 2, 3 and 
7 displayed moderate antimutagenic activity in both 
tested concentrations. The inhibition percentages for 
these compounds were between 25 and 37. Only 
compound 6 when tested in lower concentration 
exhibited weak antimutagenic effect with inhibition rate 
of 18%. 
 
Table 5. Antimutagenic activity of azinesulfonamides in the 
Ames test. 
Compd 
Concentration 
(ng/ml) 
Ames test 
TA100
a
 
Mean ± S.D. Inhib. (%)
c
 
DMSO  12 ± 5  
NQNO 40 33 ± 4  
 500 75 ± 11  
1 40 17 ± 6 (48) 
 500 48 ± 9 (36) 
2 40 23 ± 10 (30) 
 500 55 ± 8 (27) 
3 40 24 ± 2 (27) 
 500 56 ± 8 (25) 
4 40 25 ± 4 (24) 
 500 37 ± 6 (51) 
5 40 17 ± 6 (48) 
 500 43 ± 3 (43) 
6 40 27 ± 2 (18) 
 500 56 ± 13 (25) 
7 40 24 ± 3 (27) 
 500 47 ± 7 (37) 
8 40 25 ± 3 (24) 
 500 43 ± 9 (43) 
Aripiprazole 40 23 ± 2 (30) 
 500 55 ± 2 (27) 
 a
Number of revertants; 
b
NQNO (nitroquinoline-N-oxide, 40 
ng/ml, 500 ng/ml) - positive control; DMSO - negative 
control; 
c
The values in parenthesis are the inhibition rates 
(%) of mutagenicity. 
 
Discussion 
Determination of a mutagenic potential of new 
compounds is an essential component of regulatory 
toxicology.
12,31,32
 Its highly recommended to perform 
genetic toxicology screening studies in the early stage of 
product development to minimize potential mutagenic 
activity of new molecules and to prioritize structural 
modifications.  
In the present study we evaluated mutagenic and 
antimutagenic properties of the new bioactive quinoline- 
and isoquinoline-sulfonamide derivatives of long-chain 
arylpiperazines using the combination of both in silico 
and in vitro methods. With a view to develop new 
alternative approaches to safety testing we employed the 
Vibrio harveyi assay to assess compounds muta- and 
antimutagenicity. This assay, based on the detection of 
colonies of neomycin-resistant mutants appearing 
frequently after a contact with mutagens, was shown to 
be of sensitivity equal to or higher than that of the Ames 
test, depending on the nature of a tested mutagen.
20
 
Using the V. harveyi assay it is possible to detect 
significantly lower concentrations (such as 40 ng/ml) of 
typical chemical mutagens than when employing the 
Ames test. Additionally, in the present study the standard 
Ames test was used to check the reliability of OSIRIS 
Property Explorer and Vibrio harveyi prediction. 
Structural modifications within evaluated compounds (1–
8) comprised diversification of the kind of azinyl moiety, 
introduction of a flexible (three- and four methylene 
groups spacer) and semi-rigid alkylene linker, and 
variation of the position of the halogen atoms in the 
phenylpiperazine moiety. Quinoline- and isoquinoline-
sulfonamides of LCAPs containing monochloro-
substituted phenylpiperazine (1, 2) were classified as 
multireceptor 5-HT1A/5-HT2A/5-HT7/D2/D3 ligands, 
which behaved as 5-HT2A/5-HT7/D2 antagonists. 
Compound 3 was classified as 5-HT2A/5-HT7/D2/D3 
ligand. However, azinesulfonamides containing 2,3-
diClPhP (4–8) were classified as potent, multireceptor 5-
HT1A/5-HT2A/5-HT7/D2/D3 ligands and behaved as 5-
HT1A receptor partial agonist/5-HT2A and 5-HT7 receptor 
antagonist/D2 receptor partial agonists. Such receptor 
profile and the functional properties of the investigated 
agents were similar to those reported for aripiprazole. It’s 
worth noting, that aripiprazole, a reference drug 
approved for the treatment of schizophrenia and 
depression, was classified as a neuroprotective agent 
based on non-clinical studies using transformed cell lines 
and in vivo stress and lesion paradigms.
33,34
 Additionally, 
aripiprazole inhibited chronic mild stress induced 
accumulation of ROS.
4
  
Firstly, the tested compounds were submitted to in silico 
toxicity screening using the OSIRIS program. It was 
found that compounds containing 7-quinolinyl fragment, 
namely 5 (N-(3-(4-(2,3-dichlorophenyl)piperazin-1-
yl)propyl)quinoline-7-sulfonamide) and 6 (N-(4-(4-(2,3-
Dichlorophenyl)piperazin-1-yl)butyl)quinoline-7-
sulfonamide) trigger a mutagenic structural alert and 
should be consider potentially hazardous. Subsequently, 
all the tested compounds were evaluated in vitro using 
the Vibrio harveyi assay and the Ames test. Contrary to 
the preliminary in silico data, none of the compounds 
showed mutagenic activity on V. harveyi BB7, BB7M, 
BB7X and BB7XM and S. typhimurium TA100 strains. 
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Interestingly, in general mutagenic indexes was lower in 
S. typhimurium TA100 strain than in V. harveyi strains. 
This phenomenon could be explained in terms of a 
higher sensitivity of the Vibrio harveyi mutagenicity 
assay in comparison to the Ames test.  
All of the tested azinesulfonamide derivatives of long-
chain arylpiperazines displayed a protective effect 
against the mutagenicity induced by a direct acting 
mutagen NQNO in the Vibrio harveyi and the Ames 
assays with inhibition percentages ranging from 22 to 84 
in V. harveyi assay and from 18 to 51 in the Ames test. 
The most beneficial antimutagenic properties showed 
compound 5 which exhibited strong antimutagenic 
properties in all tested V. harveyi strains. High 
antimutagenic potency of this compound was confirmed 
in the Ames TA100 assay system. Moreover, 
antimutagenic effects of compounds 7 and 8 obtained in 
Vibrio harveyi were closely related to the Ames test. In 
can be concluded that antimutagenicity data are 
comparable between Vibrio harveyi and Salmonella 
assays. Only in case of compounds 3, 6 and aripiprazol 
small discrepancy exists between the data obtained in 
these two antimutagenicity tests.  
The inhibitory effects of tested azinesulfonamides 1–8 on 
the mutagenicity of NQNO indicated that these 
compounds may protect the bacterial genome against 
genotoxicity induced by directly acting mutagens. 
Although the tested compounds may exert their 
antimutagenic actions by more than one mechanism, it 
seems probable that tested compounds facilitate or 
stimulate the bacterial transmembrane export system to 
eliminate the mutagen. Alternative mechanism may 
involve uptake of mutagen into bacteria.
35
 In addition, as 
NQNO is an oxidative mutagen that undergoes redox 
recycling to generate ROS
36
 the antimutagenic action of 
tested compounds may be attributed to the inhibition of 
free radicals formation. However, further studies are 
required in order to establish the exact mechanism of 
these compounds action. 
 
Conclusion 
Newly synthesized azinesulfonamide analogs of 
aripiprazole may be considered as genotoxically safe as 
they do not display mutagenic activity on the tester 
strains. Moreover, the tested compounds demonstrated 
significant antimutagenic properties that can be valuable 
for prevention of the NQNO genotoxicity. The present 
study showed that although the results of in silico 
analysis are informative and accurate for some structural 
classes, they have often limited application for prediction 
of mutagenic properties of the novel classes of 
compounds. Thus, experimental verification of structural 
alerts for such compounds should be always considered. 
Additionally, it appears that the Vibrio harveyi assay can 
be applied for primary mutagenicity and 
antimutagenicity assessment of chemical substances, 
thus, representing a useful alternative tool for 
compounds safety evaluation. Finally, the obtained 
preliminary mutagenicity and antimutagenicity results 
encourage further search in the group of quinoline- and 
isoquinoline-sulfonamide derivatives of long-chain 
arylpiperazines as potential psychotropic agents that 
additionally display antimutagenic properties.  
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